Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
111 Inc (YI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/20/2025: YI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.96
1 Year Target Price $5.96
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.3% | Avg. Invested days 22 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/20/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 60.07M USD | Price to earnings Ratio - | 1Y Target Price 5.96 |
Price to earnings Ratio - | 1Y Target Price 5.96 | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 4.14 - 12.90 | Updated Date 06/29/2025 |
52 Weeks Range 4.14 - 12.90 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.17 |
Earnings Date
Report Date 2025-06-19 | When - | Estimate - | Actual -0.2802 |
Profitability
Profit Margin -0.48% | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -0.03% | Return on Equity (TTM) -7.73% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 19534374 | Price to Sales(TTM) - |
Enterprise Value 19534374 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 0.01 | Enterprise Value to EBITDA 37.4 | Shares Outstanding 5067440 | Shares Floating 70009558 |
Shares Outstanding 5067440 | Shares Floating 70009558 | ||
Percent Insiders 15.84 | Percent Institutions 23.69 |
Analyst Ratings
Rating - | Target Price 5.96 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
111 Inc
Company Overview
History and Background
111, Inc. (YI) was founded in 2010 and is headquartered in Shanghai, China. It operates as an integrated online and offline healthcare platform, connecting consumers to pharmaceutical products and healthcare services.
Core Business Areas
- B2C Online Pharmacy: Direct sales of pharmaceutical products, nutritional supplements, medical devices, and other healthcare products to consumers through its online platform, 111.com.cn.
- B2B Pharmaceutical Distribution: Distribution of pharmaceutical products to pharmacies and other healthcare providers.
- Online Healthcare Services: Provides online consultation, electronic prescriptions, and other healthcare services through its platform.
Leadership and Structure
The leadership team includes Junling Liu (Chairman and CEO) and other key executives. The organizational structure is typical of a publicly traded company, with a board of directors and various departments.
Top Products and Market Share
Key Offerings
- Pharmaceutical Products: Includes prescription and over-the-counter drugs. They are a large segment of their revenue. Competitors include JD Health and Alibaba Health.
- Nutritional Supplements: Vitamins, minerals, and other supplements. Competitors include GNC and NBTY.
- Medical Devices: Blood pressure monitors, glucose meters, and other medical devices. Competitors include Omron and Roche.
- Healthcare Services: Online consultations and e-prescriptions. Competitors are Ping An Good Doctor, and WeDoctor.
Market Dynamics
Industry Overview
The healthcare industry in China is experiencing rapid growth due to an aging population, rising income levels, and increasing healthcare awareness. Online healthcare platforms are becoming increasingly popular.
Positioning
111, Inc. aims to be a leading integrated online and offline healthcare platform in China. Its competitive advantages include its extensive product portfolio, strong online presence, and strategic partnerships with pharmaceutical companies and healthcare providers.
Total Addressable Market (TAM)
The total addressable market for healthcare products and services in China is substantial and continues to grow. While precise TAM figures fluctuate, it is estimated to be in the hundreds of billions of dollars. 111 Inc. is positioned to capture a growing share of this market through its integrated platform.
Upturn SWOT Analysis
Strengths
- Integrated online and offline platform
- Extensive product portfolio
- Strong online presence
- Strategic partnerships
Weaknesses
- Reliance on regulation in China
- Limited profitability
- High operating expenses
Opportunities
- Growing healthcare market in China
- Increasing adoption of online healthcare services
- Expansion into new product categories and services
- Strategic acquisitions
Threats
- Intense competition
- Changing regulations
- Economic downturn in China
Competitors and Market Share
Key Competitors
- JD (JD)
- Alibaba Health (0241.HK)
- Ping An Healthcare and Technology (01833.HK)
Competitive Landscape
111, Inc. faces intense competition from larger players with greater resources. However, its integrated platform and focus on customer service give it a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is needed to complete this section.
Future Projections: Future growth projections data is needed to complete this section.
Recent Initiatives: Focus on increasing its user base, expanding its product portfolio, and strengthening its strategic partnerships.
Summary
111, Inc. is a player in the rapidly growing Chinese online healthcare market. Its integrated online and offline platform provides a competitive advantage. However, the company faces challenges related to profitability and competition from larger players. It needs to effectively capitalize on market growth to achieve sustainable success. The company also needs to be mindful of Chinese regulations.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, market research reports, analyst estimates.
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About 111 Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2018-09-12 | Co-Founder, Acting CFO, Chairman & CEO Mr. Junling Liu | ||
Sector Healthcare | Industry Medical Distribution | Full time employees 1238 | Website https://corporate.111.com.cn |
Full time employees 1238 | Website https://corporate.111.com.cn | ||
111, Inc., together with its subsidiaries, operates an integrated online and offline platform in the healthcare market in the People's Republic of China. It operates in two segments, B2C and B2B. The company offers supply chain integration services that help pharmaceutical companies manage products through online and offline channels; product promotion, customer analytics, patient education, and brand awareness services; and marketing and channel data services. It also provides 1 Pharmacy online wholesale pharmacy that offers pharmaceutical and other health and wellness products; and 1 Medicine Marketplace online retail pharmacy that provides pharmaceutical products and other merchandise. In addition, the company offers online loan application services; cloud-based inventory management services; smart procurement services, which collect pharmacies' historical purchase orders and inventory data; and Hawkeye automated salesforce tool. Further, it provides drugs, including prescription and over-the-counter drugs comprising Western and Chinese medicines; nutritional supplements, such as vitamins and dietary products; contact lenses; medical supplies and devices that consists of bandages and thermometers; and personal care products that include skin care, birth control, sexual wellness, and baby products. Additionally, the company offers research and development, and consulting services; warehousing, procurement, and logistics services; and software development and information technology support services. It serves pharmacies, pharmaceutical companies, medical professionals, and insurance companies. The company was formerly known as New Peak Group and changed its name to 111, Inc. in April 2018. 111, Inc. was founded in 2010 and is headquartered in Shanghai, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.